Evidence map›Paper›PMID 40879465›Full record

Observational studyCancer medicine2025

Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase.

Daniele Caracciolo, Giuseppe D'Aquino, Caterina Froio, Caterina Romeo, Vincenzo Bosco, Giulia Pensabene, Ludovica Tedesco, Pierosandro Tagliaferri, Pierfrancesco Tassone

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniele CaraccioloDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.ORCID https://orcid.org/0000-0001-7870-7565
Giuseppe D'AquinoDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.
Caterina FroioDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.
Caterina RomeoDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.
Vincenzo BoscoDepartment of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
Giulia PensabeneDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.
Ludovica TedescoDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.
Pierosandro TagliaferriDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.
Pierfrancesco TassoneDepartment of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic significantly increased mortality risks for individuals with hematological malignancies. PATIENTS AND

methodsWe conducted a single-center observational study, focusing on the late pandemic phase of the infection (2022-2023), to identify risk factors associated with COVID-19 outcomes in vaccinated patients with hematological malignancies.

resultsEighty-five COVID-19 cases were recorded among patients with hematological malignancies, primarily Multiple Myeloma (MM) (38.8%), chronic lymphocytic leukemia (CLL) (10.6%) and Non-Hodgkin Lymphoma (NHL) (35.3%). Despite a high COVID-19 vaccination rate (97.6%), severe/critical illness occurred in 23.5% of patients. The overall COVID-19-related mortality rate was 22.4%, with a 30-day mortality rate of 11.8%. Although mortality rates significantly decreased over the observation time (27.7% vs. 16.7%), this trend was not confirmed in critical infection carriers.

conclusionOur data confirm that, despite a reduction in critical infections and overall mortality rates over time, patients with hematological malignancies remain at high risk during the endemic phase of SARS-CoV-2 infection.

Indexed as

COVID-19Hematologic NeoplasmsAdultAgedAged, 80 and overCOVID-19 VaccinesFemaleHumansMaleMiddle AgedRisk FactorsSARS-CoV-2COVID-19 Vaccineschronic lymphocytic leukemiaCOVID‐19hematologic malignancieslate pandemic phasemultiple myelomamyelodysplastic syndromenon‐Hodgkin lymphoma

Identifiers

PMID40879465
PMCPMC12311482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.